Closed

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Federal funding opportunity PAR-25-051 from National Institutes of Health (Department of Health and Human Services).

Posted: September 25, 2024
Closed: August 18, 2026
Cost sharing: No
Instrument: Cooperative Agreement
Assistance listing: 93.121, 93.867, 93.279, 93.853, 93.242, 93.273, 93.213, 93.866
Category: Education, Health
Archives: September 23, 2026

Program funding history

Awards made under Assistance Listing 93.121 (one of 8 on this opportunity) across FY2025–FY2027, from public federal spending records.

FY2025 obligated: $378.9M
FY2026 obligated: $380.8M
FY2027 (to date) obligated: $0
Awards in window: 2,170

Top recipients: Regents of the University of California, San Francisco, the, Regents of the University of Michigan, University of Pittsburgh - of the Commonwealth System of Higher Education, University of Florida, University of Southern California

Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →

This opportunity is closed. Applications are no longer accepted. Similar grants are listed below, and the free Tuesday digest carries the next ones like it.

Synopsis

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Who can apply

Private institutions of higher education
Native American tribal governments (Federally recognized)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Public and State controlled institutions of higher education
Small businesses
State governments
County governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
City or township governments
Special district governments

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

The official record

Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.

View on Grants.gov Full announcement

Agency contact: National Institutes of Health · [email protected] · 301-402-2541

New to federal funding? How to read an announcement · Who can apply · How grants work

Tell me when this program posts again

This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.

Stored once per grant, used only for this watch’s emails; every one carries a one-click unsubscribe. Privacy

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.

No spam, ever. Privacy

Similar grants

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
PAR-24-293 · National Institutes of Health · closes August 18, 2027
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development
PAR-28-043 · National Institutes of Health
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
PAR-25-352 · National Institutes of Health · closes October 25, 2027
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
PAR-25-353 · National Institutes of Health · closes October 25, 2027
Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
PAR-27-081 · National Institutes of Health · closes March 5, 2027
NIH Blueprint Initiative: Tools for Germline Gene Editing in the Nervous System
RFA-DA-27-012 · National Institutes of Health

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.

Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.

See pricing